(S1 (S (S (S (NP (DT The) (NN SV40) (JJ small) (NN t-antigen)) (VP (VP (VBZ prevents) (NP (JJ mammary) (NN gland) (NN differentiation))) (CC and) (VP (VBZ induces) (NP (NP (NP (NN breast) (NN cancer)) (NN formation)) (PP (IN in) (NP (JJ transgenic) (NNS mice))))))) (: ;) (S (NP (NP (VBN truncated) (JJ large) (NN T-antigen) (NNS molecules)) (VP (VBG harboring) (NP (NP (NP (DT the) (JJ intact) (NN p53)) (CC and) (NP (NN pRb))) (NN binding) (NN region)))) (VP (VBP do) (RB not) (VP (VB have) (NP (DT this) (NN effect)))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (ADVP (RB here)) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (, ,) (SBAR (SBAR (IN that) (S (NP (DT the) (NN SV40) (JJ small) (NN t-antigen)) (VP (VBZ inhibits) (NP (JJ mammary) (NN gland) (NN differentiation)) (PP (IN during) (NP (NN mid-pregnancy)))))) (CC and) (SBAR (IN that) (S (NP (NP (QP (RB about) (CD 10)) (NN %)) (PP (IN of) (NP (JJ multiparous) (NN WAP-SVt) (JJ transgenic) (NNS animals)))) (VP (VBP develop) (NP (NP (NN breast) (NNS tumors)) (PP (IN with) (NP (NP (NNS latencies)) (VP (VBG ranging) (PP (IN from) (NP (CD 10-17) (NNS months))))))))))))) (. .)))
(S1 (S (S (NP (NN Cyclin) (NN D1)) (VP (VBZ is) (VP (VP (VBN deregulated)) (CC and) (VP (ADVP (IN over)) (VBN expressed) (PP (PP (IN in) (NP (NP (DT the) (JJ small) (NN t-antigen) (JJ positive) (JJ mammary) (NN gland) (JJ epithelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS ME-cells)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (DT the) (NN breast) (NN tumor) (NNS cells)))))))) (. .)))
(S1 (S (S (S (NP (NP (NP (NN SV40) (JJ small) (NN t-antigen)) (VBN immortalized) (NNS ME-cells)) (PRN (-LRB- -LRB-) (NP (NN t-ME-cells)) (-RRB- -RRB-))) (VP (VBP exhibit) (NP (NP (DT a) (JJ strong) (JJ intranuclear) (NN cyclin) (NN D1)) (NN staining)) (, ,) (ADVP (RB also)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ external) (NN growth) (NNS factors))))))) (CC and) (S (NP (DT the) (NNS cells)) (VP (VBP continue) (S (VP (TO to) (VP (VB divide) (PP (IN for) (NP (NP (JJ several) (NNS days)) (PP (IN without) (NP (NN serum))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN expression) (NN rate)) (PP (IN of) (NP (NP (NP (NN cyclin) (NN E)) (CC and) (NP (NN p21-LRB-Waf1-RRB-))) (CONJP (CC but) (RB not)) (PP (IN of) (NP (NN p53)))))) (VP (VBZ is) (VP (VBN increased)))) (. .)))
(S1 (S (S (NP (NN Coimmunoprecipitation) (NNS experiments)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN p21-LRB-Waf1-RRB-)) (VP (VBZ is) (ADVP (RB mainly)) (VP (VBN associated) (PP (PP (IN with) (NP (DT the) (NN cyclin) (NN D/CDK4))) (CC but) (PP (RB not) (IN with) (NP (DT the) (NN cyclin) (NN E/CDK2) (NN complex)))))))))) (. .)))
(S1 (S (S (S (NP (JJ WAP-SVT) (JJ transgenic) (NNS animals)) (VP (VBP exhibit) (NP (DT an) (ADJP (RB almost) (JJ regular)) (JJ mammary) (NN gland) (NN development)) (PP (IN until) (NP (JJ late) (NN pregnancy))))) (CC but) (S (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (DT the) (NNS ME-cells)))) (VP (VBP are) (VP (VBN eliminated) (PP (IN by) (NP (NN apoptosis))) (PP (IN during) (NP (DT the) (JJ early) (NN lactation) (NN period))))))) (. .)))
(S1 (S (S (NP (NN Tumor) (NN formation)) (VP (VBZ is) (VP (VP (VBN delayed)) (CC and) (ADJP (RBR less) (JJ efficient) (PP (IN than) (PP (IN in) (NP (JJ T/t-antigen) (JJ positive) (NNS animals)))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Sequestration)) (PP (IN of) (NP (NP (NN p53)) (CC and) (NP (NN pRb)))) (PP (IN by) (NP (NP (DT the) (JJ N-terminal) (VBN truncated) (NN T-antigen) (NNS molecules)) (PRN (-LRB- -LRB-) (NP (NP (NN T1-antigen)) (CC and) (NP (NN T2-antigen))) (-RRB- -RRB-))))) (VP (VBZ does) (RB not) (VP (VB affect) (NP (JJ mammary) (NN gland) (NN differentiation))))) (CC and) (S (NP (NP (DT the) (JJ transgenic) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NN WAP-SVBst-Bam)) (-RRB- -RRB-))) (VP (VBP do) (RB not) (VP (VB develop) (NP (NN breast) (NNS tumors)))))) (. .)))
